1xbet 모바일 Pharmaceutical Co., Ltd.

1xbet 모바일 Pharmaceutical Co., Ltd. (1xbet 모바일) announces that it has decided jointly with Takara Bio Inc, (Takara Bio) to terminate agreements on co-development and exclusive marketing of NY-ESO-1・siTCR^®gene therapy product (development code: TBI-1301).

1xbet 모바일 and Takara Bio have been jointly developing NY-ESO-1・siTCR^®gene therapy for synovial sarcoma in Japan and preparing for the submission for manufacturing and marketing approval. However after comprehensive discussions between the two companies on policies and strategies related to this product, 1xbet 모바일 and Takara Bio have agreed to terminate this agreement. This decision is not due to any efficacy or safety issues of the product.

Under this termination, Takara Bio regains technical, intellectual property and other rights granted by Takara Bio to 1xbet 모바일. In addition, in the future Takara Bio will not receive lump-sum payments upon achievement of milestones under this agreement or receive any sales proceeds for clinical trial product sales.